| About the author: |
Seredynska N.M., Korniyenko V.І., Мokhort М.А., Yeromina H.О., Ieromina Z.G., Ladohubets О.V., Duchenko K.A. |
| Heading |
EXPERIMENTAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The purpose of the work was to study the anti-edema activity of leflunomide in combination with celecoxib and amlodipine under the conditions of experimental rheumatoid arthritis associated with arterial hypertension. Experiments were carried out on sexually mature nonlinear white rats of both sexes with a starting weight of 201.56 ± 2.42; (n = 174). Experimental RA was induced by subcutaneous injection of the complete AF into the plantar part of the posterior (left) limb. The drugs under study were: leflunomide (LF), 20 mg tablets; celecoxib (CC), 100 mg capsules, and amlodipine (AM), 10 mg tablets. Under the conditions of experimental RA that developed against the background of AH, there was a significant increase in the foot volume by 136-147 % (from 1.16 RU to 2.74 RU) compared to the values in animals of the intact group. Combined application of CC with LF against the background of the combined pathology led to a significant, compared to data in animals with a combined pathology and in rats treated with LF only, reduction in foot volume by 14.4-45.2 % and by 18-41.4 % respectively at all terms of observation. Particularly significant this effect was in the acute development of AA against the background of hypertension. With combined use of leflunomide, celecoxib and amlodipine only in the acute period of inflammation that develops against the background of arterial hypertension, an anti-edema effect is recorded at the level of 12%, which is significantly reduced in other observation periods. |
| Tags |
leflunomide, anti-edema, rheumatoid arthritis, arterial hypertension, comorbid pathology |
| Bibliography |
- Badokin VV. Leflunomid – modifikator techeniya i iskhodov revmatoidnogo artrita. Effektivnaya farmakoterapiya. Revmatologiya. Travmatologiya. Ortopediya. 2015; 47(3-4):20–28. [in Russian]
- Kovalenko VN, Bortkevich OP. Novaya strategiya terapii revmatoidnogo artrita (na osnovanii peresmotra rekomendatsiy Yevropeyskoy antirevmaticheskoy ligi po lecheniyu sinteticheskimi i biologicheskimi bazisnimi bolezn-modifitsiruyushchimi antirevmaticheskimi preparatami. Ukr. revmatol. zh-l. 2013; 4(54): 97–104. [in Russian]
- Lebedeva MV, Beketov VD, MaltsevaNV, Safarova ME. Effektivnost i bezopasnost antagonistov kaltsiya digidropiridinovogo ryada u bolnykh s arterialnoy gipertenziyey: mesto amlodipina. Ratsionalnaya farmakoterapiya v kardiologii. 2013; 9(1):86–89. [in Russian]
- Myasoyedova SE. Rasprostranennost i faktory riska arterialnoy gipertenzii pri revmatoidnom artrite. Nauchno-prakticheskaya revmatologiya. 2012; 51(2):31–34. [in Russian]
- Nasonov YeL, Lukina GV, Sigidin YaA. Kombinirovannaya terapiya rituksimabom i leflunomidom pri revmatoidnom artrite (predvaritelnyye rezultaty rossiyskogo ARBITR). Nauchno-prakticheskaya revmatologiya. 2011; (1):16–20. [in Russian]
- Novikova DS, Popkova TV, Nasonov YeL. Arterialnaya gipertenziya pri revmatoidnom artrite. Nauchno-prakt. Revmatologiya. 2011; (3):52–68. [in Russian]
- Rodionov A.V. Nesteroidnyye protivovospalitelnyye preparaty i arterialnaya gipertenziya: aktualnost problemy i taktika vedeniya patsiyentov. Lechashchiy vrach. 2013; (2):25–31. [in Russian]
- Savustyanenko AV. Farmakologicheskiye i terapevticheskiye aspekty primeneniya amlodipina. Arterialnaya gipertenziya. 2010; (3):45–49. [in Russian]
- Seredynska NM, Omelyanenko ZP, Khomenko VS. Kombinovane zastosuvannya antyhipertenzyvnykh i nesteroyidnykh protyzapalnykh preparativ: problemy ta perspektyvy. Naukovyy zhurnal MOZ Ukrayiny. 2015; 7(1):46–56. [in Ukrainian]
- Seredinskaya NN, Pavlyuk GV, Kirichok LM. Analgeticheskaya aktivnost Amlodipina pri adyuvantnom artrite. Curierul Medicum 2013; 56(4):28–31. [in Russian]
- Antivalle M, Chevallard М, Battellino М. Reduced response to biologic treatments in rheumatoid arthritis patients affected by arterial hypertension. Arthr. Rheum. 2013; 65(10):462 –465.
- Atar D, Birkeland KI, Uhlig T. “Treat to target”: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. Ann. Rheum. Dis. 2010; (69):629–630.
- Nikiphorov E, Guh D, Bansback N. Work disability rates in RA. Results from an inception cohort with 24 years follow–up. Rheumatology (Oxford) 2012; 51: 385–392.
- Singh JA, Furst DE, Bharat A. American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Research 2012; 64(5):625–639.
- Tanushree R, Saikat G. Animal models of rheumatoid arthritis: correlation and usefulness with human rheumatoid srthritis. Am. J. Pharm. Research 2013; 3(8): 6131-6142.
|
| Publication of the article |
«World of Medicine and Biology» №1(71), 2020 year, 218-223 pages, index UDK 615.276:615.72-002-036.8-092.9 |
| DOI |
10.26724/2079-8334-2020-1-71-218-223 |
